The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
196 reports and counting
Verve Therapeutics Raises $213M in Series C
Verve Therapeutics, a Biotech company based in 26 Landsdowne Street, Cambridge, MA 02139, has raised $213M in Series C at a $1B valuation led by Foresite Capital, GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital.
Verve Therapeutics raises $213M Series C at $1B valuation
Verve Therapeutics raises $213M in Series C at $1B valuation. Gene editing for heart disease...
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Expedition Therapeutics raises $165M Series B at $850M valuation
Expedition Therapeutics raises $165M in Series B at $850M valuation. Developing novel therapeutics for cardiometabolic diseases...
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Kailera Therapeutics raises $400M in Series A at $1.5B valuation. Developing obesity therapeutics with acquired pipeline...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.